HC Wainwright Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price

Key Points

• HC Wainwright raised Roivant Sciences’ price target to $47 from $41 and maintained a “Buy” rating, implying approximately 10.64% upside from the reported share price.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and average price target of $37.68, although ratings range from “Strong Buy” to “Sell.”
• ROIV shares rose to $42.48, near their 12-month high, while the company continues to report losses; insiders sold more than 3 million shares worth approximately $107.3 million over the past 90 days.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) had its price objective hoisted by equities researchers at HC Wainwright from $41.00 to $47.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 10.64% from the stock's current price.

Several other equities analysts also recently commented on the company. Sanford C. Bernstein upgraded Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Tuesday, August 25th. Bank of America reiterated a "neutral" rating on shares of Roivant Sciences in a research report on Friday, July 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Finally, Piper Sandler restated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $37.68.

Roivant Sciences Price Performance

ROIV stock traded up $7.55 during trading on Tuesday, reaching $42.48. 15,408,797 shares of the company were exchanged, compared to its average volume of 6,190,787. The company has a market capitalization of $30.68 billion, a price-to-earnings ratio of -79.75 and a beta of 1.12. The company has a 50-day moving average of $35.30 and a two-hundred day moving average of $31.26. Roivant Sciences has a twelve month low of $12.90 and a twelve month high of $42.25.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to analysts' expectations of $2.06 million. On average, analysts forecast that Roivant Sciences will post -2 EPS for the current year.

Insiders Place Their Bets

In other news, Director Daniel Gold sold 800,000 shares of the company's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the sale, the director directly owned 13,701,546 shares of the company's stock, valued at approximately $473,388,414.30. This represents a 5.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares of the company's stock, valued at approximately $675,364,288.75. This trade represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,055,913 shares of company stock worth $107,261,258. 8.80% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Roivant Sciences during the 1st quarter valued at $3,957,000. Bank of America Corp DE grew its holdings in Roivant Sciences by 8.0% in the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company's stock worth $87,638,000 after purchasing an additional 235,493 shares during the period. Baader Bank Aktiengesellschaft acquired a new stake in Roivant Sciences in the fourth quarter worth $1,029,000. Nicholas Investment Partners LP increased its stake in Roivant Sciences by 13.9% in the fourth quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company's stock valued at $6,073,000 after purchasing an additional 34,235 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Roivant Sciences in the fourth quarter valued at $76,272,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Key Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant and its Pulmovant subsidiary reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD), a serious condition with substantial unmet medical needs. The company also disclosed that the Phase 3 PHrontier study is underway, providing a potential path toward a larger value-creating catalyst. Roivant Announces Positive Results from PHocus Study
• Positive Sentiment: Coverage highlighted that mosliciguat met the goals of its mid-stage study, helping drive investor enthusiasm and positioning the drug as a potentially important lung-disease asset. Roivant’s Experimental Lung Disease Drug Meets Goals
• Positive Sentiment: Jefferies raised its price target for ROIV to $52 from $42 and maintained a Buy rating, reflecting increased confidence following the clinical update. Unusually heavy call-option buying also indicates elevated near-term bullish speculation.
• Positive Sentiment: Roivant and Priovant reportedly received FDA approval for Lisraya, described as the first oral treatment for dermatomyositis. The approval gives the partners a differentiated commercial product in a rare disease with limited treatment options. Roivant Wins Approval for the First Oral Dermatomyositis Drug
• Neutral Sentiment: Lisraya launched with a reported list price of $35,000 per 30-day supply, underscoring substantial revenue potential but leaving reimbursement, patient access, and adoption as key commercial risks. What Lisraya’s $35,000 Monthly Price Could Mean for Roivant

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.